These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
227 related articles for article (PubMed ID: 36344419)
1. Outcomes of Autologous Stem Cell Transplantation as a Consolidative Strategy for the Treatment of Primary and Isolated Secondary Central Nervous System Diffuse Large B Cell Lymphomas. Sahin U; Gokmen A; Soydan E; Urlu SM; Merter M; Gokgoz Z; Arslan O; Ozcan M Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e1-e13. PubMed ID: 36344419 [TBL] [Abstract][Full Text] [Related]
2. Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. Young PA; Gaut D; Kimaiyo DK; Grotts J; Romero T; Chute J; Schiller G; de Vos S; Eradat HA; Timmerman J Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):468-479. PubMed ID: 32229199 [TBL] [Abstract][Full Text] [Related]
3. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients. Schorb E; Finke J; Ihorst G; Kasenda B; Fricker H; Illerhaus G BMC Cancer; 2019 Mar; 19(1):287. PubMed ID: 30925912 [TBL] [Abstract][Full Text] [Related]
4. The role of whole-brain radiotherapy (WBRT) in primary central nervous system lymphoma: is it an alternative to ASCT for consolidation following HD-methotrexate based induction in low-income settings? de Pádua Covas Lage LA; Araújo Soares V; Meneguin TD; Culler HF; Reichert CO; Jacomassi MD; Reis DGC; Zerbini MCN; de Oliveira Costa R; Rocha V; Pereira J Radiat Oncol; 2022 Oct; 17(1):171. PubMed ID: 36273167 [TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom. Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466 [TBL] [Abstract][Full Text] [Related]
7. A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime. Bairey O; Lebel E; Buxbaum C; Porges T; Taliansky A; Gurion R; Goldschmidt N; Shina TT; Zektser M; Hofstetter L; Siegal T Hematol Oncol; 2023 Dec; 41(5):838-847. PubMed ID: 37403752 [TBL] [Abstract][Full Text] [Related]
8. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Tun AM; Wang Y; Maliske S; Micallef I; Inwards DJ; Habermann TM; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB Transplant Cell Ther; 2024 Oct; 30(10):1001.e1-1001.e12. PubMed ID: 38996973 [TBL] [Abstract][Full Text] [Related]
9. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells. Landsburg DJ; Nasta SD; Svoboda J; Gerson JN; Schuster SJ; Barta SK; Chong EA; Difilippo H; Weber E; Cunningham K; Catania C; Garfall AL; Stadtmauer EA; Frey NV; Porter DL Transplant Cell Ther; 2023 Aug; 29(8):495-503. PubMed ID: 37211154 [TBL] [Abstract][Full Text] [Related]
10. Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma. Haeno T; Rai S; Miyake Y; Inoue M; Fujimoto K; Fujii A; Iwata Y; Minamoto S; Taniguchi T; Kakutani H; Inoue H; Kumode T; Serizawa K; Taniguchi Y; Hirase C; Morita Y; Tanaka H; Tatsumi Y; Ashida T; Matsumura I J Clin Exp Hematop; 2023 Jun; 63(2):99-107. PubMed ID: 37121716 [TBL] [Abstract][Full Text] [Related]
11. Consolidative Autologous Stem Cell Transplantation Versus Whole Brain Radiation in PCNSL; a Nationwide Analysis. Samhouri Y; Mustafa Ali MK; Law J; Khan C; Wegner R; Lee ST; Lister J Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):735-743. PubMed ID: 35705438 [TBL] [Abstract][Full Text] [Related]
12. Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning. Arshad S; Fang X; Ahn KW; Kaur M; Scordo M; Sauter CS; Furqan F; Awan FT; Hamadani M Bone Marrow Transplant; 2023 Nov; 58(11):1203-1208. PubMed ID: 37563283 [TBL] [Abstract][Full Text] [Related]
13. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839 [TBL] [Abstract][Full Text] [Related]
14. Autologous Stem Cell Transplantation in Central Nervous System Lymphoma: A Multicenter Retrospective Series and a Review of the Literature. Dholaria BR; Kumar A; Azzuqua AG; Nishihori T; Kharfan-Dabaja MA; Tun HW; Ayala E Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e273-e280. PubMed ID: 30914301 [TBL] [Abstract][Full Text] [Related]
15. Consolidative Radiotherapy After Autologous Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B-cell Lymphoma. Coutu BG; Wilke CT; Yuan J; Cao Q; Vernon MR; Lee C; Bachanova V; Dusenbery KE Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):65-73. PubMed ID: 29079283 [TBL] [Abstract][Full Text] [Related]
17. Autologous stem cell transplant in recurrent or refractory primary or secondary central nervous system lymphoma using thiotepa, busulfan and cyclophosphamide. Welch MR; Sauter CS; Matasar MJ; Faivre G; Weaver SA; Moskowitz CH; Omuro AM Leuk Lymphoma; 2015 Feb; 56(2):361-7. PubMed ID: 24745937 [TBL] [Abstract][Full Text] [Related]
18. Disease status at autologous stem cell transplantation and the cell of origin phenotype are important predictors of outcome in patients with neurologic (central nervous system) relapse of diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Patil S; Spencer A; Schwarer A; Avery S; Ritchie D; Opat S; Wei A; McLean C Leuk Lymphoma; 2009 Dec; 50(12):1964-8. PubMed ID: 19860614 [TBL] [Abstract][Full Text] [Related]
19. A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma. Habringer S; Demel UM; Fietz AK; Lammer F; Schroers R; Hofer S; Bairey O; Braess J; Meier-Stiegen AS; Stuhlmann R; Schmidt-Hieber M; Hoffmann J; Zinngrebe B; Kaiser U; Reimer P; Möhle R; Fix P; Höffkes HG; Langenkamp U; Büschenfelde CMZ; Hopfer O; Stoltefuß A; La Rosée P; Blasberg H; Jordan K; Kaun S; Meurer A; Unteroberdörster M; von Brünneck AC; Capper D; Heppner FL; Chapuy B; Janz M; Schwartz S; Konietschke F; Vajkoczy P; Korfel A; Keller U Eur J Cancer; 2024 Jan; 196():113436. PubMed ID: 38008033 [TBL] [Abstract][Full Text] [Related]
20. Long-term outcomes of frontline intensification in primary CNS lymphoma: A real-world single-center experience. Wang HY; Yang CF; Lin CH; Hsiao LT; Ko PS; Liu YC; Chiou TJ; Chen PM; Gau JP; Liu JH; Liu CJ Cancer Med; 2023 Apr; 12(7):8089-8101. PubMed ID: 36647765 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]